(2E)-N-[(4-Chlorophenyl)methyl]-3-(4-propoxyphenyl)prop-2-enamide

Catalog No.: 
ACSXSL942
CAS No.: 
329779-72-8
Molecular Formula: 
C19H20ClNO2
Molecular Weight: 
329.83
(2E)-N-[(4-Chlorophenyl)methyl]-3-(4-propoxyphenyl)prop-2-enamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg90%$106.00InquiryInquiry
1g90%$322.00InquiryInquiry
5g90%$1578.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(2E)-N-[(4-Chlorophenyl)methyl]-3-(4-propoxyphenyl)prop-2-enamide
IUPAC Name(E)-N-(4-chlorobenzyl)-3-(4-propoxyphenyl)acrylamide
Molecular FormulaC19H20ClNO2
Molecular Weight329.83
SMILESO=C(NCC1=CC=C(Cl)C=C1)/C=C/C2=CC=C(OCCC)C=C2
InChI KeyYWPOEFUTMKFNCC-KPKJPENVSA-N
SynonymN-(4-CHLOROBENZYL)-3-(4-PROPOXYPHENYL)ACRYLAMIDE;(2E)-N-[(4-chlorophenyl)methyl]-3-(4-propoxyphenyl)prop-2-enamide;2-Propenamide, N-[(4-chlorophenyl)methyl]-3-(4-propoxyphenyl)-
CAS No.329779-72-8

Synthetic Route by SureRoute

1. ACSXSL942 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACQDJE308 route compound structure diagram
    ACQDJE30842365-43-5In Stock
  4. Then
  5. ACSXSL942 route product structure diagram
    ACSXSL942329779-72-8
Inquiry

2. ACSXSL942 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACQDJE308 route compound structure diagram
    ACQDJE30842365-43-5In Stock
  4. Then
  5. ACSXSL942 route product structure diagram
    ACSXSL942329779-72-8
Inquiry

3. ACSXSL942 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSXSL942 route product structure diagram
    ACSXSL942329779-72-8
Inquiry

Comments (0)